Remove 2019 Remove Documentation Remove Vaccines
article thumbnail

First COVID-19 impact report on global vaccine markets

European Pharmaceutical Review

The World Health Organization (WHO)’s Global Vaccine Market Report 2022 , the first report to examine the impact of COVID-19 on the global vaccine market, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently fighting to access vaccines in demand by wealthier countries.

article thumbnail

The imperative of fridge-free vaccines

European Pharmaceutical Review

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top biopharmaceutical Covid-19 vaccine companies boosted with over 80% revenue growth

Pharmaceutical Technology

Last year was a positive year for biopharmaceutical companies, particularly those with Covid-19 vaccines. As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. YoY revenue growth.

Vaccines 108
article thumbnail

STAT+: Pharmalittle: We’re reading about Gilead’s CMO leaving, Novartis hedging on a drug, and more

STAT

Merdad Parsey, who joined Gilead in 2019, will stay in his post until the first quarter of next year as the company looks for a successor. Gilead Europe’s second-highest court criticized the European Commission for a lack of transparency over Covid-19 vaccine contracts four years ago , Reuters writes.

article thumbnail

Building an integrated vector supply to support autologous cell therapy for solid tumours

European Pharmaceutical Review

Within recent years this situation has been further exacerbated by the COVID-19 pandemic: both directly, through viral vaccine manufacture; and indirectly, through instability in global supply chains. An analysis performed at the end of 2019 concluded that demand for viral vectors would have surpassed CDMO capacity during 2020.

Vaccines 115
article thumbnail

From start to finish – digitising clinical trials

pharmaphorum

Nearly every element of the clinical trial design, data collection, analysis and approvals has been shortened and this helped ensure the swift rollout of safe and effective vaccines.”. Thankfully, paper-based studies are becoming a thing of the past, but spreadsheets and Word documents are still commonly used to design and build trials.

article thumbnail

Innovation and collaboration – the MHRA’s pandemic approach

pharmaphorum

The pandemic has propelled issues for the pharmaceutical industry to the top of the political and public agenda, from clinical trial recruitment to the journey required for medicines or vaccines to reach patients. Getting the UK’s COVID vaccine and treatments programme ahead of schedule. Why is this important for the UK?